News | May 05, 2022
Israeli researchers warn about the return of Delta variant
The research was supported by the BGU Coronavirus Challenge and the Israeli Ministry of Health.
The research was supported by the BGU Coronavirus Challenge and the Israeli Ministry of Health.
Air purification system achieves Intertek zero ozone certification
The study will be published on the pre-print server, medRXiv, shortly
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Subscribe To Our Newsletter & Stay Updated
